Equity and Funding Terms Across Major Accelerators

I've sat through a few of these negotiations, and here's the thing nobody tells you going in: an accelerator check buys a permanent stake in your company that doesn't evaporate when the batch ends. Every deal reduces to two numbers, cash in and equity out, but the instrument they use to get you there (fixed stake versus something convertible) shapes your outcome just as much as the percentage on the page. Skip the mechanics and you're signing away things you can't grab back later.

Quick vocabulary check, because half the confusion in these deals comes from founders nodding along in a room without knowing what they just agreed to. An equity stake is ownership that transfers the moment ink hits paper, fixed and permanent. Dilution is what happens to your percentage every time new shares get issued; the pie just got cut into more pieces and your slice shrank. A convertible instrument means cash shows up now but the ownership math happens later, usually at your next raise. A valuation cap puts a ceiling on the conversion price, so an early investor doesn't get diluted into nothing if your valuation takes off. And an MFN clause (most favored nation) means if you later give someone better terms, your accelerator gets those terms too, automatically, no renegotiation needed.

You'll need all five of these terms before this is over.

How the SAFE became the standard instrument for early-stage accelerator deals

Before 2013, pre-seed deals ran mostly on convertible notes, which are debt. Debt carries interest and a maturity date, and a maturity date means that if you haven't closed a priced round by then, somebody's forcing a conversion or asking for cash back. Rough spot to be in when you're three people in a garage still arguing about whether the product actually works.

Carolynn Levy, YC's longtime lawyer, fixed this in 2013 by writing the SAFE (Simple Agreement for Future Equity). The contract carries no debt and no interest, and it says: equity comes later, once a real valuation exists, and until then nobody has to sweat a deadline. That one change took the artificial urgency out of the room.

The SAFE caught on because it let companies close in days instead of weeks, and it let everyone defer the hardest question (what's this company actually worth right now?) to a point when there's more evidence on the table. YC revised the template again in 2018, moving from pre-money to post-money SAFEs. That sounds like a rounding error, but it isn't one. Post-money SAFEs tell you your exact dilution the day you sign, instead of leaving it fuzzy until three more SAFEs stack on top and nobody can do the math anymore.

Four flavors exist: cap only, cap plus discount, discount only, neither. Cap-only shows up most often, and the cap itself moves depending on traction. The cap is the ceiling price at which the SAFE converts into shares, protecting the investor if your valuation goes vertical.

Founders rarely get warned about what happens next. SAFEs are so easy to sign that founders sign four or five of them over 18 months, each at a different cap. Fast forward to Series A, and a chunk of the company's future equity was already spoken for before the priced round even opened. None of this shows up as a warning label. It shows up on the cap table one Tuesday afternoon, uninvited, like a party guest nobody remembers inviting who's somehow already eaten half the cheese plate.

Y Combinator's deal structure in concrete terms

YC's current terms, in place since 2022, are blunt on purpose: $500,000, flat, same number for every company in every batch. There's no haggling, no pitching for more, and nobody's negotiating you down either. It's $500,000, period.

Split that check in two and the actual complexity shows up.

$125,000 buys a fixed 7% stake, locked the day you sign. No surprises there, you know the cost cold. The other $375,000 comes through an uncapped MFN SAFE, meaning there's no ceiling on the conversion price. YC just waits, and whatever terms you negotiate with your next real investor, YC automatically gets those same terms too, courtesy of the MFN clause. No cap, no back-and-forth, just a bet that they'll ride along on whatever deal you land next.

The real price of that $375,000 chunk, as a result, is unknown on signing day. It depends entirely on your next raise, and founders sometimes assume the full investment costs one clean percentage. Only the smaller fixed piece is knowable up front; the rest is a bet on your future self.

Money hits the account once you're accepted, not once you clear some milestone, and there's nothing to unlock along the way. You're in, and the wire goes out.

So what's the equity actually buying, beyond cash? A founder network past 11,000 people, mentors who've built and sold real companies, and a brand signal that changes how investors read you after Demo Day. Whether 7% is a fair price for that is your call to make, but the track record gives you something to weigh it against: 82 unicorns, 17 public companies, combined alumni valuation north of $600 billion. Roughly 70% of YC companies that raise a Series A do it within 18 months of Demo Day, and median seed round size for recent batches landed around $3.1 million in 2025. Each batch now runs 250 to 300 companies, four times a year.

How other major accelerators structure their deals differently

Nobody standardized any of this. Walk from one accelerator's term sheet to the next and the architecture, the check size, the instrument itself, all of it changes.

Techstars, with terms refreshed for 2026, mirrors YC's two-part setup: small fixed slice, larger uncapped MFN SAFE riding behind it. Smaller check, smaller fixed stake, but you're buying a different network and often a different geography for that discount. Techstars reports that a strong majority of its graduates raise capital within three years of finishing the program.

500 Global goes the other direction entirely: fixed equity only, no SAFE, tied to a four-month in-person program. That's easier to understand at a glance, though you give up the flexibility that comes from punting the valuation conversation down the road.

SOSV, running programs like IndieBio and HAX, writes bigger checks because deep tech and biotech take years, not months, and the money comes in tranches rather than one lump sum. That structure makes sense once you consider the alternative: nobody funds a decade of biotech runway the same way they'd fund a weekend hackathon idea that turned into a company.

Then there's the zero-equity lane. MassChallenge takes no fees and no equity at all, running purely on prize money and program resources, and its alumni have raised real capital without giving up a single share at the door. Plug and Play skips equity too, though it dangles optional follow-on investment through its venture arm from seed through Series A. Both fit founders who don't need the cash urgently, or who'd rather test-drive the accelerator experience before trading away ownership for it.

On the far end, a handful of programs take unusually large stakes, usually the ones building a company from raw idea or writing bigger checks than typical pre-seed. That's fair, assuming the involvement is early and hands-on enough to earn it. The real comparison never comes down to percentage against percentage. It's what each program actually delivers relative to what it costs, and that answer depends on your sector, your geography, your stage.

What dilution actually means across the life of a company

Every founding team starts at 100%, and every round after that shrinks it. That's the whole system in one sentence.

The accelerator's stake is your first dilution event, but rarely your biggest. Seed, Series A, the employee option pool, they all stack, and by Series C, median founder ownership has historically dropped below the size of the employee option pool combined. Sit with that for a second: the people writing code and answering support tickets today often, collectively, own more of the company than the person who started it.

Higher valuations mean less dilution per dollar raised, so the broader fundraising climate matters more than founders usually credit it for. The option pool itself, typically a significant percentage of fully diluted shares at seed, needs to sit in your mental math right alongside whatever the accelerator's asking for.

Run the actual number. A 7% stake at a $10 million post-money valuation has a real dollar price tag attached. Whether the accelerator's network, mentorship, and name recognition are worth that price is the question you need to answer honestly, before you sign, not after.

SAFE stacking deserves a second mention here, because it's the part that sneaks up on people. Several SAFEs at different caps, signed across 18 months, quietly commit a big chunk of your future cap table before any priced round ever happens. SAFEs work fine individually, but the terms just add up, so track every single one the same way you'd track calories if you were actually serious about the diet and not just talking about starting one Monday.

How co-founder equity splits interact with accelerator terms

The accelerator's stake dilutes the whole founding team proportionally, whether that feels fair in the moment or not. A split that made sense at 2 AM in month one has a way of curdling into resentment once outside money shows up and everyone's suddenly doing math on their phones.

Equal splits have gotten more common, for a decent reason: more teams now have every co-founder full-time and committed from day one, so a 50-50 split reflects real parity instead of just avoiding an awkward conversation. Equal splits carry their own failure mode, though. Two people at 50-50 with no tiebreaker can deadlock on a decision, and board control turns murky fast the moment the relationship sours even slightly.

Some teams use dynamic equity models, sometimes called slicing pie, tracking actual contribution over time and adjusting ownership as the company moves. That's more setup work, but it buys more accuracy. Vesting matters just as much as the split itself; investors, accelerators included, want to see structured vesting because it means equity gets earned over time, and that protects everyone if a co-founder walks after six months.

Solo founders make up a real chunk of new incorporations but a much smaller slice of venture-backed companies, and that gap is worth sitting with before deciding to go it alone. Settle the internal equity structure and vesting schedule before any outside investor enters the room, accelerator included. Fixing it after the deal is signed is a brutal conversation, and it tends to happen at exactly the moment you can least afford it. YC's co-founder matching platform, for what it's worth, has facilitated a large number of matches, so founders still hunting for a partner have a place to start before they even fill out an application.

What to evaluate before accepting an accelerator's terms

Check size and the headline equity number are the parts everyone sees immediately. The MFN clause, cap-versus-uncapped structure, and pro rata rights are the parts that actually determine your outcome three years out, and they're the parts most founders skim past on their way to signing.

Ask plainly, before you sign anything. Is this fixed equity, a SAFE, or some blend, and if it's a SAFE, what's the cap and what triggers conversion? If there's an MFN clause, what exactly are you committing to hand this investor down the line? How many SAFEs already sit on your cap table, and what does combined dilution look like once a priced round finally lands? Does the program hold pro rata rights, meaning the right to invest again in future rounds, and on what terms?

For a program like YC, the equity buys access to a network past 11,000 founders and a brand signal that changes how investors treat you after Demo Day. That's real value, no argument there, but estimate it honestly instead of assuming it's worth whatever they ask just because the name carries weight in the room.

Zero-equity programs earn the same scrutiny, not less. No dilution doesn't mean no cost. You're still trading time, attention, and sometimes exclusivity for capital and access, and that trade deserves the same hard look as any equity deal. The right program depends on your sector, your stage, your geography, and what you're actually short on right now, whether that's cash, customers, co-investors, or plain credibility heading into the next round.

The goal is knowing, in specific and unambiguous terms, what you're trading and whether the trade makes sense for your company today. Read the SAFE, read the MFN clause twice, then decide, with your eyes open, instead of just being grateful somebody wrote you a check.